Ovarian cancer G-protein-coupled-receptor-1 (OGR1) is a tumor metastasis suppressor in prostate cancer (PCa). OGR1 knockout mice (ogr1 À / À ) are grossly normal under physiological conditions, however, reduced melanoma tumorigenesis has been observed, with the mechanisms of this reduction completely unknown. In this work, we demonstrated that OGR1 deficiency in host cells significantly reduced tumorigenesis of PCa in mice. Adoptive transfer of WT CD11b þ Gr1 þ double positive (DP) cells, but not T cells, was sufficient to allow tumor development in ogr1 À / À mice. The expression of an M1 macrophage marker, inducible nitric oxide synthase (iNOS) was higher and expression of an M2 macrophage marker, arginase-1 (Arg 1) was lower in tumors from ogr1 À / À mice compared with WT mice. Furthermore, coinjection of transgenic adenocarcinoma mouse prostate (TRAMP)-C2 cells with WT, but not ogr1 À / À macrophages, increased tumor incidence in ogr1 À / À mice. T-cell depletion experiments suggested that T cells were required for tumor rejection in ogr1 À / À mice, although OGR1 expression in T cells may not be necessary. In summary, the expression of OGR1 in myeloid-derived cells, especially in DP cells, was required for PCa tumor cell-induced immunosuppression.
INTRODUCTION
The ovarian cancer G-protein-coupled-receptor-1 (OGR1) subfamily of G-protein-coupled receptor is composed of four members: OGR1, GPR4, G2A and TDAG8, all of which have proton-sensing activity and are regulated by certain lipid molecules.
1,2 These G-proteincoupled receptors also appear to have ligand-independent constitutive activity. 3 To further understand the physiological role of OGR1, we have generated ogr1 À / À mice. 4 Which are viable and upon gross-inspection appear normal. However, thioglycolateinduced peritoneal macrophages from ogr1 À / À mice showed altered extracellular signal-regulated kinase activation and nitric oxide production in response to lipopolysaccharide. 4 Unexpectedly, we have found that melanoma tumorigenesis is significantly inhibited in OGR1 deficient mice, 4 suggesting that in contrast to its tumor-suppressing role in tumor cells, host cell OGR1 may be involved in and/or required for tumor growth. However, the types of host cells and the mechanisms by which host-cell OGR1 affects tumorigenesis are completely unknown.
As we have shown that OGR1 is a metastasis-suppressor gene when it is expressed in prostate cancer (PCa) tumor cells, 3 it is of great interest to test the role of host cell OGR1 in PCa development. The transgenic adenocarcinoma mouse prostate (TRAMP) and RM-9 mouse PCa cell lines were used to explore the roles of host-cell OGR1 in WT and ogr1 À / À mice. 5, 6 The tumor microenvironment is a complex milieu of tumor and host cells. The tumor and host components interact to generate a highly immune-suppressive environment that reduces T cell cytotoxicity and promotes tumor progression. 7 The well-known immune cell types involved in tumor-induced immunosuppression include myeloid-derived suppressor cells (MDSC), regulatory T cells (Treg), and tumorassociated macrophages. MDSC are immature myeloid cells. Under physiological conditions, they differentiate into dendritic cells, macrophages and granulocytes. 8, 9 In particular, MDSC suppress T-cell function by multiple mechanisms including depletion of L-arginine by arginase-1 (Arg 1), generation of reactive oxygen species and nitric oxide species by inducible nitric oxide synthase (iNOS) and sequestration of cysteine, an amino acid that T cells are unable to synthesize de novo and that they require for activation. 10 In mice, MDSC are characterized by CD11b and Gr1 expression. Functional involvement of MDSC in tumor development has been demonstrated by administration of monoclonal antibodies against MDSC or drugs which block their function. [11] [12] [13] [14] There are two distinct stages of macrophage differentiation: type I macrophages (M1 macrophages) are proposed to be tumoricidal, producing nitric oxide and proinflammatory factors, including interleukin (IL-12) and tumor necrosis factor alpha (TNFa). M2 macrophages synthesize arginase, but not iNOS. 15, 16 They produce antiinflammatory molecules such as IL-4, IL-13 and IL-10 17 and have protumor function. MDSC bear characteristics of precursors for both M1 and M2 macrophages. 18 Tumors have been shown to induce M1 À M2 conversion. 19 In this work, we characterized host OGR1-dependent PCa tumorigenesis by comparing tumor incidence/size in WT and ogr1 À / À mice. We studied the mechanisms of OGR1's effect and identified the cell types involved using bone marrow transplantation (BMT), adoptive transfer, host-tumor cell coinjection, T-cell depletion, and immune-cell biological studies. The functions of OGR1 in myeloid cells shown here are novel and may shed light for developing new strategies against PCa.
RESULTS
PCa tumorigenesis was significantly reduced in OGR1 deficient mice To determine the role of host OGR1 in PCa development, TRAMP-C2 cells were subcutaneous injected into WT and ogr1 À / À mice.
In a total of five independent sets of experiments, large subcutaneous tumors developed in 23 of 23 WT mice, while only 7 of 45 ogr1 À / À mice developed tumors ( Figure 1a ). In addition, the tumors from ogr1 À / À mice (tumor volume ¼ 85.4±104 mm 3 ) were significantly smaller when compared with those developed in the WT mice (tumor volume ¼ 4135 ± 2330 mm 3 ; Po0.0001) at 45 days post-tumor cell injection (Figures 1b and c) . Ki-67 staining showed that the proliferation rate was higher in the WT tumors when compared with ogr1 À / À tumors (Figure 1d) (Figures 2a  and b) . These results were reproducible in three independent studies, suggesting that WT-BMDC have dominant roles and are sufficient to support tumor growth in ogr1 À / À mice.
CD11b
þ Gr1 þ double positive (DP) cells from WT mice were sufficient to permit tumor growth in ogr1 À / À mice It was noted that after TRAMP-C2 tumor challenged, the average spleen weights in WT mice were increased from 0.08 g to40.2 g, while a lesser increase was observed in ogr1 À / À mice (from 0.08 to 0.1 g) (Figures 3a and b) . The corresponding total number of splenocytes (in millions) from WT tumor bearing mice (mean ¼ 268.3±36.8) were significantly higher than those from ogr1 À / À mice (mean ¼ 173.3 ± 32.2,) (P ¼ 0.0282) (Figure 3c ). This was accompanied by a significant increase in the % of DP cells and a decrease in the % of CD4 þ and CD8 þ cells in WT spleen and blood (Figures 3d-f ). As no significant differences in these cell populations were detected between spleen and blood from naive WT and ogr1 À / À mice, these changes were likely induced by To investigate which cell type(s) derived from BMDC was/were functionally involved in the OGR1-depenedent immunosuppression, we performed adoptive transfer experiments. In addition to T cells, dendritic cells and activated macrophages, we showed that CD11b þ Gr1 þ DP cells express ogr1 by reverse transcription-PCR (Figure 3g ). We confirmed that DP cells from WT mice were capable of suppressing CD8 þ T cell proliferation ex vivo, and thus these cells were MDSC by definition ( Figure 3h ).
Injection of un-fractionated splenocytes from tumor-challenged WT mice were sufficient to permit tumor growth in ogr1 À / À mice (n ¼ 4) (Figure 4a ). To further address whether CD11b þ Gr1 þ DP or T cells were functionally involved in OGR1-depedent PCa tumorigenesis, we purified these two subsets of cells from the spleens of tumor-bearing WT mice. The purity of DP cells and CD3 þ T cells was B90% ( Figure 4b ). All ogr1 À / À mice that received WT-DP cells grew tumors (n ¼ 5) (Figure 4a ). In contrast, injection of WT CD3 þ T cells did not significantly affect TRAMP-C2 tumor development in ogr1 À / À mice (only two in five developed small tumors; Figure 4a ). In addition, injection of splenocytes from naive WT mice on the same day as tumor inoculation was also able to induce tumor development in five of five mice tested (Figure 4a ), suggesting that pre-exposure to tumor antigens was not necessary for the immunosuppression observed. We also noticed that although TRAMP-C2 tumors grew progressively in WT splenocyte or DP cell adoptively-transferred ogr1 À / À mice, the tumor growth rate was slower than that in WT mice, suggesting potential contributions of other host cells.
WT and ogr1
À / À splenocytes differentially responded to TRAMP-C2 cells ex vivo To determine the effect of OGR1 deficiency on cytokine production in response to tumor cells, splenocytes were isolated from tumor challenged WT and ogr1 À / À mice and cocultured with irradiated TRAMP-C2 cells in vitro. We found that several tumor-promoting cytokines, including IL-6, IL-10 and TNF-a, were significantly reduced in cocultured ogr1
À / À vs WT splenocytes (Figures 5a-c). Control cells (either irradiated TRAMP-C2 cells or non-stimulated WT and ogr1 À / À splenocytes) produced none or very low levels of cytokines.
M1 and M2 macrophage markers were differentially expressed in tumors from WT and ogr1 À / À mice and WT macrophages were sufficient to support TRAMP-C2 tumor growth in ogr1 À / À mice MDSC bear characteristics of precursors for both M1 (tumoricidal) and M2 (tumor-promoting) macrophages 18 and can be differentiated into M2 macrophages in the tumor microenvironment. 22 We examined whether OGR1 had an effect on macrophage polarization and whether differentiated macrophages had a similar OGR1-dependent effect as MDSC in PCa tumorigenesis. We found that F4/80 positive macrophages were not differentially infiltrated into tumors from WT vs ogr1 À / À mice, suggesting that OGR1 does not affect macrophage infiltration and/or differentiation ( Figure 6a ). However, immunohistochemistry (IHC) analyses showed that the expression of iNOS, an M1 macrophage marker was higher in tumors from ogr1 À / À mice (Figure 6a ). In contrast, the expression of arginase 1 (Arg 1), an M2 macrophage marker, was higher in tumors from WT mice (Figure 6a ). These results suggest that OGR1 may have a critical role in M1 À M2 conversion and/or in the process of MDSC to M2 macrophage differentiation.
To test the role of OGR1 in macrophages in TRAMP-C2 tumorigenesis more directly, a coinjection experiment was conducted. Coinjection of thioglycolate-induced macrophages (M1) from WT, but not those from ogr1 À / À mice, increased tumorigenesis in ogr1 À / À mice and five of eight ogr1 À / À mice developed tumors (average size 7368 mm 3 ) 85 days after tumor challenge (Figure 6b ). The tumor-associated macrophages were converted to an M2 phenotype, as evidenced by increased Arg 1 and reduced iNOS expression (Figure 6c ). While these data indicate that expression of OGR1 in myeloid-lineage cells are important for OGR1's protumor function, the longer time (85 vs 45 days) needed for tumor development after injection of M1 cells implies that expression of OGR1 in other cells may also be involved in supporting tumor growth.
Both CD4
þ and CD8 þ T cells were required for tumor rejection in (Figure 7a ). Angiogenesis assessed by CD31 staining was also similar in tumors from either group (Figure 7a ). On the other hand, infiltration of CD4 þ and CD8 þ T cells was significantly increased in tumors from ogr1 À / À mice compared with tumors from WT mice (Figures 7b and c) , suggesting that T cells may be involved in tumor development. As Treg are involved in immune suppression, we also examined levels of Foxp3 þ Treg cells. Although the total numbers of Foxp3 þ cells were increased in tumors from ogr1 À / À mice, the ratio of tumor infiltrating FoxP3 þ Treg to CD4 þ cells was not significantly different in tumors from WT and ogr1 À / À mice (Figures 7d and e) .
To determine whether T cells were functionally involved in the ability of ogr1 À / À mice to reject tumor cells, CD4 þ and CD8 þ T cells were depleted in ogr1 À / À mice. All four CD4 þ T cell depleted ogr1 À / À mice (490% depleted in blood) grew tumors (Figure 7f) . Three of four CD8 þ T cell depleted ogr1 À / À mice (470% depleted in blood) grew tumors (Figure 7g ). The CD8 þ T-cell depletion was only 30% in one mouse that did not grow tumors. These data suggest that both CD4 þ and CD8 þ T cells are involved in TRAMP-C2 tumor rejection in ogr1 À / À mice, and may function as effector cells in tumor rejection. 
DISCUSSION
Our previous work showed that tumorigenesis of murine melanoma cell xenografts in ogr1 À / À mice was reduced; however, the mechanisms of this reduction are completely unknown. 4 In this study, we first demonstrated that OGR1 deficiency significantly reduced tumorigenesis of PCa in mice, indicating that the effect is not limited to one tumor type. Tumor cells are well known to be able to induce immunosuppression, allowing tumors to grow. We identified the cell type functionally involved in this phenotype, and showed that adoptive transfer of DP cells isolated from WT but not from ogr1 À / À mice was necessary and sufficient to support tumor growth and reduce tumor rejection in ogr1 À / À mice. In addition, the expression of an M1 macrophage marker (iNOS) was higher and expression of an M2 macrophage marker (Arg 1) was lower in tumors from ogr1 À / À mice compared with WT mice. Furthermore, WT macrophages coinjected with tumor cells increased TRAMP-C2 tumorigenesis in ogr1 À / À mice. Together, our data suggest that OGR1 expression in myeloid lineage cells has an important role in tumor cell-induced immunosuppression.
Our BMT and adoptive transfer experiments suggest that OGR1 expression in myeloid-derived cells is sufficient to mediate immunosuppression and allow tumors to grow. At the molecular level, OGR1 expression in these cells affects expression of several cytokines associated with tumor growth, including IL-6, IL-10 and TNF-a. IL-6 is a cytokine that promotes tumor growth, angiogenesis and metastasis. 25 IL-10 is an immunosuppressive cytokine consistently expressed in the tumor microenvironment. TNF-a has pluripotent effects on tumorigenesis and tumor progression, and it is produced by both the tumor and the tumor microenvironment. 
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Thus, OGR1 is likely to be involved in protumor cytokine expression/ secretion in the tumor microenvironment. The mechanisms by which OGR1 regulates these processes remain to be further investigated.
OGR1 is also expressed at high levels in CD4 þ and CD8 þ T cells ( Figure 3) . We found an increased infiltration of these T cells in the subcutaneous tumors from ogr1 À / À mice ( Figure 7 ) and depleting CD4 or CD8 T cells resulted in tumor rejection ( Figure 7 ). These findings support the notion that T cells are important in ogr1 À / À mice tumor rejection. However, adoptive transfer of WT T cells did not significantly affect tumorigenesis in ogr1 À / À mice (Figure 4) , suggesting that OGR1 expression in these T cells was not critical in PCa tumorigenic effects studied in this work.
The OGR1 gene has been shown to be expressed at lower levels in human metastatic compared with primary PCa tissues. 26 We have shown that OGR1 is a new metastasis suppressor gene when it is expressed in tumor cells in PCa using human PCa cells. 3 To study the role of OGR1 in host cells, we need to use mouse models and have chosen the TRAMP-C2 cells in syngeneic C57BL/6 mice 27 TRAMP-C2 is of epithelial origin, as with major human PCa. 6 In addition, TRAMP-C2 shows similarities with human PCa in terms of genetic and epigenetic alterations. 28 TRAMP-C2 or TRAMP tumors share many common tumor antigens with human PCa's such as prostate stem cell antigen, stimulator of prostatic adenocarcinoma-specific T cells, prostatic acid phosphatase and prostate-specific membrane antigen. 29 Characterization of the TRAMP-C2 cell lines indicates that the TRAMP model is an appropriate model for identifying immunotherapeutic strategies for human PCa. 30 In particular, it has been shown that TRAMP-C2 is a suitable animal model for the study of the role of the mechanisms of tumor escape from immune surveillance and it is a useful model for evaluating preventive and therapeutic approaches for human PCa. 31, 32 Although human diseases or pathophysiological conditions related to a genetic defect in ogr1 have not been identified, the novel roles of OGR1 in myeloid cells revealed in this work have laid an important basis for developing novel strategies to against prostate and potentially others cancers.
Collectively, our results suggest that OGR1 expression in myeloid-derived cells, particularly in DP cells, is important for tumor cell-induced immunosuppression and tumor development, perhaps by promoting M2 macrophage development and inhibiting T-cell infiltration. However, OGR1 expression in other cells may play additional roles to accelerate tumor growth. These 
MATERIALS AND METHODS Mice
The ogr1 À / À mice have been previously described. 4 Both WT and ogr1 À / À mice were from the C57/BL6 background (BL6; 10 generation backcrossing). C57/BoyJ F1 mice were obtained from the in vivo Therapeutics Core facility of Indiana University Simon Cancer Center. All mice were maintained under specific pathogen-free conditions and all studies complied with relevant federal guidelines and policies of the Laboratory Animal Resource Center at Indiana University School of Medicine.
Cell lines and reagents
The murine prostate adenocarcinoma TRAMP-C2 line was a kind gift from Dr Richard P Ciavarra, Eastern Virginia Medical School. Cells were cultured in dulbecco's modified eagle medium supplemented with fetal bovine serum (10%), insulin (5 mg/ml) and dihydrotestosterone (10 nM) (Sigma, St Louis, MO, USA). RM-9 cells were from Dr Timothy C. Thompson 
BMT
Eight-week-old recipient mice were irradiated with 1100 rads (700 rads following 400 rads, 3 h apart). Bone marrow was flushed from femora and tibia of donor mice and 5 Â 10 6 bone marrow cells in 0.2 ml phosphatebuffered saline (PBS) were injected into the tail vein of irradiated recipient mice. Six-weeks post BMT, the mice were subcutaneously injected with 3 Â 10 6 TRAMP-C2 tumor cells in PBS (200 ml). The number of WT or ogr1 À / À BMDC transferred ogr1 À / À mice is four, respectively in each experiment. The BMT experiments were repeated three times.
Histology and immunohistochemistry
Tumors were dissected and frozen in optimal cutting temperature compound for cryosections or fixed with 10% neutral buffered formalin before paraffin embedding. For histological analysis 5-mm-thick sections were cut and stained with hematoxylin and eosin using standard protocols. Arg 1, iNOS2, NK1.1, CD31, F4/80, Ki-67 and B220 staining were performed on paraffin-embedded sections using standard techniques; primary antibodies were diluted 1:200. Tumor-infiltrating CD8 þ , CD4 þ and Foxp3 þ cells were detected on frozen sections by immunofluorescence; primary antibodies were diluted 1:200. Sections were imaged with a Nikon ECLIPSE TE2000-S microscope (Nikon, Melville, NY, USA) and analyzed using MetaMorph software (Molecular Devices, Sunnyvale, CA, USA). For all IHC stainings, at least three pairs of WT and ogr1 À / À tumor sections were tested.
In vivo T cell depletion CD4 þ or CD8 þ T cells were depleted in ogr1 À / À mice by intraperitoneal injection of depleting anti-CD4 mAb (clone YTS191.1, 250 mg per injection, n ¼ 4) and anti-CD8 mAb (clone YTS169, 300 mg per injection, n ¼ 4), respectively. Antibodies were injected 2 days before TRAMP-C2 implantation, and every 5 days post implantation for a total of six injections. Depletion of CD8 þ and CD4 þ cells was confirmed by FACS analysis of peripheral blood cells and found to be 490%.
T cell proliferation assay
Ninety-six -well plates were coated with an anti-CD3e antibody solution (50 ml (10 mg/ml) per well) (Ebioscience 145-2C11, San Diego, CA, USA), incubated at 4 1C overnight and washed. Splenocytes in single cell suspensions were collected from either ogr1 À / À or WT mice. After removing red blood cells using RBC lysis buffer, splenocytes were labeled with the fluorescent dye 5,6-carboxy-fluorescein succinimidyl ester. Carboxyfluorescein diacetate N-succinimidyl ester-labeled cells (0.2 ml (10 6 cells/ml) per well) were seeded in anti-CD3e-coated plates in the presence of anti-CD28 (2 mg/ml). DP cells isolated from spleens of TRAMP-C2 tumor bearing mice were cocultured with splenocytes in different ratios. After a 4-day incubation, cells were collected and stained with CD8-PE mAbs. T cell proliferation was determined by FACS analysis. This experiment was repeated twice.
Tumor xenograft models TRAMP-C2 tumor cells (3 Â 10 6 cells in 0.2 ml PBS) or RM-9 tumor cells (1 Â 10 5 cells in 0.2 ml PBS) were injected subcutaneously into WT and ogr1 À / À mice. Mice were sacrificed when they appeared moribund (45 days for TRAMP-C2 and 17 days for RM-9), the weight and size of the tumor was measured, the volume of tumor was calculated using the formula width 2 Â length Â 0.5. For the TRAMP-C2 xenograft model, 4-5 WT mice and 8-10 ogr1 À / À mice were used in each experiment, and 5-10 independent experiments were conducted, with a total of 23 WT and 45 ogr1 À / À mice tested. For the RM-9 xenograft model, 6 WT mice and 6 ogr1 À / À mice were used.
Flow cytometric analysis
Cells (1 Â 10 6 in 100 ml) were incubated with mAbs at 4 1C for 30 min. 
Adoptive transfer experiments
The spleens of WT TRAMP-C2 tumor bearing mice were collected 60 days post-tumor challenge and used as the source of adoptive transfer cells. The CD11b þ Gr1 þ DP cells were isolated from splenocytes using a MDSC isolation kit and an LS column (Miltenyi Biotec, Bergisch gladbach, Germany). T cells were isolated from remaining cells using a pan T cell isolation kit (Miltenyi Biotec, Bergisch gladbach, Germany). On day 1, ogr1 À / À mice were intravenously injected with different subsets of purified cell populations (5 Â 10 6 cells per mouse), followed by subcutaneous injection of TRAMP-C2 cells (3 Â 10 6 cells per mouse). On day 7 and day 14, an additional two doses of purified immune cells (5 Â 10 6 cells per mouse) were adoptively transferred via intravenous injection. Tumor development was closely monitored and tumor size was measured every 7 days. The adoptive transplantation experiments were repeated for three times using 4-5 ogr1 À / À mice in each experiment.
Cytokine measurement by enzyme-linked immunosorbent assay
Spleens of TRAMP-C2 tumor cell-inoculated mice were collected. 2 Â 10 6 cells/ml splenocytes were cocultured with irradiated TRAMP-C2 cells (20:1) in 200 ml medium in 96-well plates for 4 days. The levels of cytokines (IL-6, IL-10, TNF-a, IL-2, IL-12 and IFN-g) in the conditioned medium were measured by the corresponding R&D ELISA Kits (R&D Systems, Minneapolis, MN, USA). The experiments were repeated three times.
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Macrophage and TRAMP-C2 tumor cell subcutaneous coinjection Macrophages used for coinjection were obtained from both WT and ogr1 À / À mice after thioglycolate stimulation. Mice were intraperitoneally injected with thioglycolate (3% in 1 ml PBS) and peritoneal exudate cells were collected 5 days later. These cells were F4/80 þ (490%) as assessed by FACS analysis. Eight ogr1 À / À mice received WT macrophage and TRAMP-C2 coinjection, seven ogr1 À / À mice received ogr1 À / À macrophage and TRAMP-C2 coinjection.
Statistical analysis
Data are presented as means ± s.d. Differences between groups were determined using the Student's t-test unless otherwise noted. All statistical tests were two-sided, and P-values ofo0.05 were considered significant.
